Vertex stock price and the options call/put action reflect investors optimism in anticipation of future positive catalysts for the stock which in the short term include:
1. Clinical trial results of VX 661/770 Phase 2 study in CF
2. Announcement of a lucrative deal partnering VX 787 snf VX 509 with a larger pharma.
3. Eventual addition of Vertex to the S&P 500 (recent Forbses article last week pointed out the Vertex market cap exceeds that of companies with the lowest market caps already in the S&P 500 e.g. Humana.
4. Aniticipation of both VX 509 Phase 2 clinical trial results in RA in the second half of the year, and the six month read out of Phase 3 CF trial results with VX 809 and 770 by year end or the first quarter of next year, with Breakthrough drug designation allowing early approval of VX 809 with 770 in 2014 by the FDA.